References

Cancer statistics, 2010

2010 · External reference

Renal-cell carcinoma

10.1056/nejm199609193351207 · 1996 · External reference

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

10.1056/nejmoa003013 · 2001 · External reference

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

10.1038/nm0901-987 · 2001 · External reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

10.1126/science.1104819 · 2005 · External reference

The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib

2010 · External reference

Renal cell carcinoma: ten years of significant advances

10.1007/s11523-010-0150-9 · 2010 · External reference

New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance

10.1158/1078-0432.ccr-09-2273 · 2010 · External reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

10.1056/nejmoa065044 · 2007 · External reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

10.1200/jco.2008.20.1293 · 2009 · External reference

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors

10.1593/neo.09618 · 2009 · External reference

Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors

10.1593/tlo.10136 · 2010 · External reference

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship

2003 · External reference

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

2003 · External reference

Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

10.1007/s11523-009-0126-9 · 2009 · External reference

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3

10.1158/1078-0432.ccr-08-0652 · 2008 · External reference

Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model

10.1186/1471-2407-7-4 · 2007 · External reference

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma

10.1158/0008-5472.can-09-3722 · 2010 · External reference

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and plateletderived growth factor receptor, in patients with metastatic renal cell carcinoma

10.1200/jco.2005.02.2574 · 2006 · External reference

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

10.1093/annonc/mdn168 · 2008 · External reference

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

10.1200/jco.2007.15.6331 · 2008 · External reference

Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model

10.1158/1535-7163.1271.3.10 · 2004 · External reference

Genistein inhibits radiation-induced activation of NF-κB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest

10.1186/1471-2407-6-107 · 2006 · External reference

Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo

10.1158/0008-5472.can-06-2147 · 2007 · External reference

Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model

10.1002/ijc.22548 · 2007 · External reference

Radiation-induced HIF-1α cell survival pathway is inhibited by soy isoflavones in prostate cancer cells

10.1002/ijc.24015 · 2009 · External reference

Daidzein effect on hormone refractory prostate cancer in vitro and in vivo compared to genistein and soy extract: potentiation of radiotherapy

10.1007/s11095-010-0107-9 · 2010 · External reference

An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels

10.1093/jaoac/89.4.1121 · 2006 · External reference

Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer

10.1080/01635581.2010.509839 · 2010 · External reference

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

10.1158/0008-5472.can-04-0074 · 2004 · External reference

Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

10.1200/jco.2006.06.8080 · 2006 · External reference

Dietary isoflavones in the prevention of cardiovascular disease—a molecular perspective

10.1016/j.fct.2007.06.029 · 2008 · External reference

Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response

2002 · External reference

Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction

2003 · External reference

Targeting angiogenic processes by combination rofecoxib and ionizing radiation

10.1097/00000421-200110000-00005 · 2001 · External reference

Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts

2001 · External reference